[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Treeline Biosciences, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100608652","phase-1-tln-372-in-advanced-kras-mutant-solid-tumors-100608652",false,"NCT07204340","TLN-372 in Advanced KRAS Mutant Solid Tumors","An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors","Inclusion Criteria:\n\n1. Patients must have measurable disease at study entry.\n2. Patients must have locally advanced or metastatic KRAS mutant solid tumors.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Adequate organ function.\n\nExclusion Criteria:\n\n1. Patients must not have active brain metastases.\n2. Patients must not have current or past history of central nervous system (CNS) involvement.\n3. Patients must not have major surgery or severe trauma within 4 weeks prior to the start of the study.\n4. Patients must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places patients at unacceptable risk of participating in this study.\n5. Patients must not have clinically significant cardiovascular disease.\n6. Pregnant or lactating.\n7. Conditions that could affect drug absorption.","ALL","18 Years",{"count":19,"type":20},240,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors",[26],"KRAS Mutant Solid Tumors",[28,29],"KRAS mutant solid tumors","KRAS","RECRUITING","2026-04-20",{"date":33,"type":34},"2026-04-21","ACTUAL",{"date":36,"type":34},"2025-09-29",{"date":38,"type":20},"2032-04-01",{"name":40,"class":41},"Treeline Biosciences, Inc.","INDUSTRY",11,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100599308","phase-1-tln-121-in-relapsed-or-refractory-non-hodgkin-lymphomas-100599308","NCT07082803","TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas","An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas","Inclusion Criteria:\n\nDisease Characteristics\n\n1. Participant must have measurable disease at study entry\n2. Participants must have one of the following histologically documented hematologic malignancies:\n\n   1. Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (DLBCL, NOS), Follicular lymphoma (FL) grade 3b, or transformed lymphoma from FL following at least 2 prior lines of therapy.\n   2. FL grade 1-3a that requires treatment following at least 2 prior lines of therapy.\n   3. The following Peripheral T-cell lymphoma (PTCL) subtypes that have relapsed after, or not responded to at least 1 prior systemic treatment regimen:\n\n      * Nodal T-follicular helper (Tfh) cell lymphoma angioimmunoblastic; Follicular helper T-cell lymphoma, angioimmunoblastic type (AITL).\n      * Nodal Tfh cell lymphoma, follicular type; Follicular helper T-cell lymphoma, follicular type.\n      * Nodal Tfh cell lymphoma, NOS; Follicular helper T-cell lymphoma, NOS.\n3. High-Grade B-Cell Lymphoma that has relapsed after, or not responded to at least 2 prior systemic treatment regimens.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n1. Participants must not have current central nervous system (CNS) involvement. Participants with past history of CNS involvement of lymphoma must have had CNS disease fully treated with no evidence of recurrence within 12 months.\n2. Participant must not have a history of autologous stem cell transplantation within 60 days or allogeneic stem cell transplantation within 90 days prior to the start of the study.\n3. Participant must not have a history of CAR T-cell or other T-cell targeting treatment ≤ 4 weeks prior to the start of the study.\n4. Participant must not have major surgery or severe trauma within 4 weeks prior to the start of the study.\n5. Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.\n6. Pregnant or lactating.\n7. Conditions that could affect drug absorption.",{"count":51,"type":20},180,[23],"The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas",[55,56],"Lymphoma","Lymphoma, Non Hodgkin",[58],"Relapsed or Refractory Non-Hodgkin Lymphomas","2026-03-25",{"date":61,"type":34},"2026-03-27",{"date":63,"type":34},"2025-06-23",{"date":65,"type":20},"2030-11",{"name":40,"class":41},12,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100572451","phase-1-a-study-of-tln-254-in-participants-with-relapsed-or-refractory-t-cell-lymphoma-100572451","NCT06733441","A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma","Phase 1b, Randomized, Dose Optimization Study to Assess the Anti-Tumor Activity, Safety, and Pharmacokinetics of TLN-254 in Patients With Relapsed or Refractory T-cell Lymphoma","Inclusion Criteria:\n\nAge:\n\n1. At least 18 years of age at the time of signing the informed consent form (ICF).\n\n   Type of Participant and Disease Characteristics:\n2. Cohort 1: Peripheral T-cell lymphoma (PTCL) that has relapsed after, or not responded to at least one prior systemic treatment regimen. Participants with Anaplastic large cell lymphoma (ALCL) should have received prior brentuximab vedotin treatment.\n\n   * Nodal T-follicular helper (TFH) cell lymphoma angioimmunoblastic; Follicular helper T-cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).\n   * Nodal TFH cell lymphoma, follicular type; Follicular helper T-cell lymphoma, follicular type.\n   * Nodal TFH cell lymphoma, not otherwise specified (NOS); Follicular helper T-cell lymphoma, NOS.\n   * PTCL, NOS.\n   * Anaplastic large-cell lymphoma, Alkaline phosphatase (ALK) positive.\n   * Anaplastic large-cell lymphoma, ALK negative.\n\n   Cohort 2: Relapsed\u002Frefractory CTCL which has relapsed after, or not responded to at least two prior systemic treatments.\n   * Sezary syndrome\n   * Mycosis fungoides\n3. Participant must have measurable disease at study entry.\n4. Freshly biopsied or archival tissue available.\n\n   Diagnostic Assessments:\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n6. Adequate organ function.\n\n   Contraception:\n7. Participants must accept and follow the pregnancy prevention plan.\n\nExclusion Criteria:\n\nMedical Conditions:\n\n1. Participants must not have prior systemic anti-cancer treatment less than or equal to (≤) 5 half-lives or 4 weeks, allogeneic SCT≤90 days or autologous SCT ≤60 days prior to study intervention initiation.\n2. Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.\n3. Current or past history of central nervous system (CNS) involvement.\n\nOther Exclusions:\n\n* Pregnant or lactating women.\n* Unable to swallow tablets.",{"count":76,"type":20},50,[23],"The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.",[55],[81,82],"Relapsed or refractory Cutaneous T Cell Lymphoma","Relapsed or refractory Peripheral T Cell Lymphoma","2025-10-09",{"date":85,"type":34},"2025-10-10",{"date":87,"type":34},"2024-12-16",{"date":89,"type":20},"2028-11-15",{"name":40,"class":41},5,""]